Clinical Trial Update: A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of RC010 Inhalation Powder in Healthy Participants [Phase 1]

View source ↗

Summary

Phase 1 study to evaluate safety, tolerability and pharmacokinetics of RC010 inhalation powder in healthy participants, with idiopathic pulmonary fibrosis liste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• RC010 inhalation powder (RC010)

Snippet

Sponsor: Nanjing Reju Therapeutics Co., Ltd | Conditions: IPF | Phase 1 | Status: NOT_YET_RECRUITING